The Centers for Disease Control and Prevention (CDC) today announced a change in its guidance regarding using Nirsevimab (Beyfortus™) in a Clinician Outreach and Communication Activity email.
As of January 5, 2023, the CDC says that infants and children recommended to receive Beyfortus should be immunized as quickly as possible.
Read More
